SCHEMBL2553743

SCHEMBL2553743

N#Cc1ccc(C(F)(F)F)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.50
CCR6 P51684 1/20 0.45
KIF11 P52732 1/20 0.44
KMT2A Q03164 3/20 0.43
MAOB P27338 1/20 0.41
CTSS P25774 1/20 0.40
SCN10A Q9Y5Y9 1/20 0.39
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 1/20 0.39
NPSR1 Q6W5P4 2/20 0.38
KDM4E B2RXH2 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TRPA1 O75762 1/20 0.38
CHEK1 O14757 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP3A5 P20815 1/20 0.37
THRB P10828 1/20 0.37
MAPT P10636 1/20 0.36
FAAH O00519 1/20 0.36
ELANE P08246 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30841758 1.00 DGAT1 (0.50) DGAT1CCR6KIF11KMT2AMAOB
SCHEMBL6065413 0.94 DGAT1 (0.47) DGAT1CCR6KIF11KMT2AMAOB
SCHEMBL6065411 0.94 DGAT1 (0.47) DGAT1CCR6KIF11KMT2AMAOB
SCHEMBL6256028 0.85 DGAT1 (0.63) DGAT1CCR6KIF11CTSSTRPA1
SCHEMBL1584633 0.84 DGAT1 (0.42) DGAT1CCR6KIF11SCN10ATRPA1
SCHEMBL14676801 0.84 DGAT1 (0.42) DGAT1CCR6KIF11CTSSSCN10A
SCHEMBL11535669 0.83 ALDH1A1 (0.44) DGAT1CCR6KIF11CTSSALDH1A1
SCHEMBL21045811 0.82 DGAT1 (0.44) DGAT1KIF11CTSSNPSR1TRPA1
SCHEMBL11537287 0.82 CTSS (0.48) DGAT1CCR6CTSSSCN10AALDH1A1
SCHEMBL14973267 0.79 KMT2A (0.43) DGAT1KIF11KMT2AALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117199519-A Electrolyte, preparation method and application thereof, and lithium battery 北京纳米能源与系统研究所 2023-12-08 CN claimed
EP-4676591-A2 SMALL MOLECULE FSH RECEPTOR MODULATORS Ferring B.V. (NL) 2026-01-14 EP disclosed
US-20260001870-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2026-01-01 US disclosed
EP-4634169-A1 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF Pfizer Inc. (US) 2025-10-22 EP disclosed
US-12448371-B2 Inhibitor compounds Cincera Therapeutics Pty Ltd (AU) 2025-10-21 US disclosed
EP-4598908-A1 HSD17B13 INHIBITORS AND/OR DEGRADERS Pfizer Inc. (US) 2025-08-13 EP disclosed
WO-2025061707-A1 SYNTHESIS OF SULFOXIMINES CONTAINING A BENZIMIDAZOLE MOIETY SYNGENTA CROP PROTECTION AG (CH) 2025-03-27 WO disclosed
WO-2024184461-A2 SMALL MOLECULE FSH RECEPTOR MODULATORS FERRING B.V. (NL) 2024-09-12 WO disclosed
CN-114450281-B Inhibitor compounds 辛塞拉治疗私人有限公司 2024-08-16 CN disclosed
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders PFIZER INC. (US) 2024-07-18 US disclosed
US-5436267-A An O-(N-2-carbamylphenyl)-heterocyclic oxime; insecticides; fungicides; miticides; nematocides; plant growth regulators; herbicides; viricides; attractants ISHIHARA SANGYO KAISHA, LTD. (JP) 1995-07-25 US disclosed
EP-0498396-A2 N-phenylcarbamate compound, process for preparing the same and biocidal composition for control of harmful organisms ISHIHARA SANGYO KAISHA, Ltd. (JP) 1992-08-12 EP disclosed
US-5032607-A Enzyme inhibitors IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-07-16 US disclosed
US-4999364-A Azole derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-03-12 US disclosed
EP-0354683-A1 Azole derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-02-14 EP disclosed
US-4866086-A PHENYLTRIAZOLYL OLEFINIC AROMATASE INHIBITORS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1989-09-12 US disclosed
EP-0299683-A2 Heterocyclic olefinic compounds and their use as aromatase inhibitors IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1989-01-18 EP disclosed
EP-0034917-B1 2-SUBSTITUTED-5-TRIFLUOROMETHYLPYRIDINES AND A PROCESS FOR PRODUCING THE SAME ISHIHARA SANGYO KAISHA LTD. (JP) 1984-08-08 EP disclosed
US-4367336-A 2-Substituted-5-trifluoromethylpyridines and process for producing the same ISHIHARA SANGYO KAISHA, LTD. (JP) 1983-01-04 US disclosed
EP-0034917-A1 2-Substituted-5-trifluoromethylpyridines and a process for producing the same ISHIHARA SANGYO KAISHA LTD. (JP) 1981-09-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders HSD17B13, HSD17B3, HSD17B1 DGAT1 677/4885CCR6 4283/4885KIF11 3816/4885
US-20260001870-A1 INHIBITOR COMPOUNDS CES1, NCEH1, NR1H2 DGAT1 41/4885CCR6 946/4885KIF11 3494/4885
US-12448371-B2 Inhibitor compounds SERPINB1, MMP1, SSB DGAT1 164/4885CCR6 4390/4885KIF11 4192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.